Acute Kidney Injury and Renal Outcomes for COVID-19 Patients in Intensive Care Units

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04459975

Enrollment

200

Registered

2020-07-07

Start date

2020-04-01

Completion date

2020-11-30

Last updated

2020-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abnormalities of Urinary Analysis, on Occurrence of Acurate Kidney Injury During Intensive Care Unit

Keywords

Acurate Kidney Injury

Brief summary

The actual COVID-19 epidemy is an unprecedented healthcare problem. Although acute respiratory distress syndrome is the main organ failure, acute kidney injury (AKI) has appeared to be more frequent and more severe than expected. Some data suggested a potential direct renal tropism of the virus, or undirect injury by cytokine storm. The aims of this study are: 1. To describe incidence, severity and mortality associated with AKI during covid-19 infection in ICU 2. To identify specific risk factors for AKI 3. To explore pathophysiologic mechanism of AKI during COVID-19 infection

Interventions

OTHERNon interventional study

Comorbidities, creatinine levels, urinary analysis, hemodynamic, respiratory status, co-medication will be collected from medical files for each patient. Specific datas from patients with AKI will be collected from medical files For severe acute patients, serum and urinary analysis will performed to identify the underlying cause of kidney injury For severe AKI patients who will die, post-mortem renal biopsy will be performed, for histopathological analysis

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Confirmed COVID-19 infection (by qRT-PCR and/or TDM typical lesion) * Needing intensive care

Exclusion criteria

* End Stage Renal Disease patients (with pre-existent dialysis) * Intensive care support for less than 72h (transfer in conventional unit or death)

Design outcomes

Primary

Measure	Time frame	Description
Primary endpoint is the incidence, the severity and the mortality associated with AKI during COVID-19 severe infection	7 months	AKI will be defined according with KDIGO guidelines: increase in creatinine of more than 1,5 fold compared to baseline Severe CVOID-19 infection is defined as 1/ confirm COVID-19 infection (by TDM and/or qRT-PCR) 2/ Requirement of ICU support during more than 72h

Countries

France

Contacts

Primary ContactDenis FOUQUE, Professor

denis.fouque@chu-lyon.fr+33 472 678 704

Backup ContactMaxime ESPI

maxime.espi@chu-lyon.fr+33 472 678 704

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026